Member Info for TRENCH123

Andy, smaller losses then move to profitability is my interpretation. Transition may be sooner than we think

Your loyalty will be well rewarded IMHO

Few quick observations :-

1. PYC disappointed that cash at bank not higher than £460k. Chunk of money came in from a debtor just a day or two after financial year end

2. Six late stage business opportunities (proposals with client) and strong early stage pipeline and great momentum across the various initiatives

3. £654k in contacted work for this finiancial year already

4. PREDICT-ONC Trial - in discussions regarding the accessing of a large data set which would accelerate the tools development

There is a general summary of Physiomics on the IMC site which includes this extract 'With growing demand for model-informed drug development, biometrics, and personalised medicine, Physiomics is positioned in high-growth markets with projected double-digit CAGR across its service areas. Supported by blue-chip client relationships, increasing diversification, and a robust cash position, the Group is confident in delivering sustainable growth, enhanced profitability, and long-term shareholder value'

Extremely good and positive presentation by Pete Sargent. Well worth a watch for those genuinely interested in PYC

Apologies, presentation is at 12 noon and not 1.00pm

People genuinely interested in this share should sign up for and tune in to the company presentation by PS/JM tomorrow at 1.00pm

Will be well worth a listen and allow you to form your own judgement of progress and future prospects here

People genuinely interested in this share should ignore the background noise and listen to the full presentation by PS/JM on Wednesday

Results Monday, no fund raise in sight. Happy days

I always enjoy the detailed presentations. Looking forward to some insights from PS/JM

Trout, you sound just like Stanley in the 'Considerably Richer than You' Harry Enfield sketches !!

We’re delighted to welcome Dr Ghaith Aljayyoussi to Physiomics plc as our new Senior Quantitative Pharmacology Scientist 🎉

Ghaith is a PK/PD modelling specialist with experience spanning industry and academia. His background includes translational PK/PD modelling for neglected tropical diseases and malaria at the Liverpool School of Tropical Medicine, and most recently working as a PK/PD modeller at Boehringer Ingelheim

He brings expertise across anti-infectives, inflammatory disease, oncology and more, with expertise in dose optimisation and quantitative systems pharmacology – areas that are central to how we support our partners in developing smarter, more efficient treatments

Trout, you said you worked during the daytime. Are you a fortune teller on the Golden Mile ?

Thanks Ralph - PYC are well positioned to benefit

Https://www.physiomics.co.uk/about/team/dr-ghaith-aljayyoussi/

New article from PYC partner DosemeRx :

https://www.pharmaceuticalcommerce.com/view/precision-dosing-market-strategy-how-model-informed-tools-drive-cost-speed-access

'Precision dosing is no longer a niche clinical tool, it is a strategic asset with wide-reaching implications for commercial success. Companies that embed model-informed precision dosing into their product strategies are not only improving patient care but also enhancing their competitiveness across the pharmaceutical value chain.

As the industry moves toward value-based care, pricing pressures, and more sophisticated market access requirements, precision dosing offers manufacturers a way to demonstrate stewardship, efficiency, and innovation. When clinical outcomes and commercial results align, dosing stops being an afterthought and start being a growth driver. That’s where model-informed tools earn their place, not just in the clinic, but at the center of a company’s market strategy. For the forward-leaning pharmaceutical leader, precision dosing is more than a capability, it’s a competitive advantage'

Jaari, Pete Sargent is making good progress in a difficult market IMHO . Breakthrough press release could come sooner than you think

Close on two months since the DosemeRx RNS (extract below). I would like to think that a news update will follow in the near future

Expansion of collaboration :

Physiomics and DoseMe have recently signed non-binding Heads of Terms with the intention of expanding their partnership beyond the Company's current personalised dosing software. This agreement defines terms across four areas of collaboration:

· development and commercialisation of novel dosing software tools originating from Physiomics;

· development and commercialisation of novel dosing software tools originating from DoseMe or its clients;

· provision of consultancy services by the Company to DoseMe; and

· co-development of clinical trial dosing software in support of biopharmaceutical clients.

The two parties are actively working to identify potential projects falling under these umbrella categories and further announcements on this will be made when appropriate.

Jaari, the next 6/12 months will give us a better indication who has called it right.

It is pleasing to note that you recognise the potential of the DoseMe/Beyond Blood partnerships to transform the company

Well everybody's happy then. Let's keep it that way

Trout, it is just that you seem attracted to the share like a magnet. More interested in investors who hold shares here and who have a direct interest in the future success (or failure) of PYC

avocet123, no losses are made until you sell shares, so be patient and wait to see things unfold. Your obsession with Laura shows no sign of going away !!

Laura, Trout is 'out' by the sound of things and maybe looking for a cheaper re-entry point. Good luck to him/her